Sotrovimab

(asked on 11th May 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) availability and (b) accessibility of Sotrovimab in (i) Slough and (ii) England.


Answered by
Maggie Throup Portrait
Maggie Throup
This question was answered on 17th May 2022

Patient access to sotrovimab is clinically determined in line with the published clinical access policies. Individuals at highest risk from COVID-19 infection can access this treatment directly from COVID Medicines Delivery Units (CMDUs) or via the RECOVERY trial for patients admitted to hospital with COVID-19. The latest data shows that 24,798 patients who tested positive for COVID-19 have received sotrovimab in England, with the majority of these patients receiving treatment as non-hospitalised patients via a CMDU.

While the information relating to Slough is not held in the format requested, 2,175 patients suitable for treatment have been identified in the Frimley CDMU area, of whom 701 have been triaged for and treated with sotrovimab and 343 have received oral antiviral medication.

Reticulating Splines